GLP‑1 drugs such as Ozempic, Wegovy and Zepbound have become common treatments for diabetes and obesity and are typically prescribed as long-term therapies. Yet many patients stop taking them. An analysis of insurance claims by Dr. Jaime Almandoz, an obesity medicine specialist at UT Southwestern, found that fewer than one in four people remained on a GLP‑1 medication after one year.
People discontinue for a variety of reasons. Some view obesity treatment as temporary and stop once they reach a weight goal. Others face rising costs or loss of insurance coverage. Side effects are another frequent cause of stopping. Despite that, consumer surveys indicate most who lapse plan to resume treatment: market‑research firm Kantar reports roughly 74% of lapsers say they are likely or very likely to come back to a GLP‑1.
That intent is being reinforced by more medication options (including oral forms), lower prices for some products, and online sellers or compounding pharmacies that can make access easier and sometimes bypass traditional doctor and insurer approvals. Cultural forces — celebrity examples, social media marketing and direct‑to‑consumer ads — have normalized cycling on and off the drugs. Regulators have scrutinized some advertising by compounding pharmacies that portrayed temporary or cosmetic use as acceptable.
However, research on intermittent or on‑again/off‑again GLP‑1 use is limited. Existing studies show weight tends to return relatively quickly after stopping these medications, often faster than after behavior‑focused diet programs. Clinicians worry about the health effects of repeated short courses. A notable portion of weight lost on GLP‑1s — reported in some studies at around 40% — can be lean muscle rather than fat. Muscle loss occurs with many weight‑loss methods, but GLP‑1–associated loss can be pronounced and visible, sometimes described as a bonier or looser‑skinned appearance.
When people stop GLP‑1s, fat often returns quickly, while it’s unclear how completely or how quickly lost muscle mass is regained. If lean mass isn’t rebuilt, especially in older adults, repeated cycles could increase the risk of sarcopenia and related problems: impaired balance, reduced mobility, slower metabolism and weaker bones.
Not all experts view the muscle changes as wholly negative. Some research suggests GLP‑1s may improve muscle quality by reducing fat infiltration and producing healthier, stronger muscle fibers, so function could improve even if total muscle mass falls. Many clinicians emphasize assessing both muscle quantity and functional measures — strength, mobility and metabolic health — rather than focusing on weight or mass alone.
Overall, the growing trend of short‑term and intermittent GLP‑1 use is outpacing evidence about long‑term consequences. Key unanswered questions include how stopping and restarting affect health over time, how to preserve or rebuild lean mass during and after treatment, and how best to counsel patients weighing temporary versus continuous therapy. More research and careful clinical guidance are needed as access and demand continue to expand.